Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions:

Status Completed

Clinical Trial Summary

This prospective study aims to

1. compare the detection rates among sonography, MIBI scan and 18F-FCH PET for localization of the parathyroid lesions including adenoma, hyperplasia or carcinoma; evaluate the usefulness of 18F-FCH PET as a second-line tracer in MIBI scan negative patients.

Clinical Trial Description

Hyperparathyroidism is a common endocrine disorder. Primary hyperparathyroidism is due to over-secretion of parathyroid hormone and subsequently hypercalcemia, phyophosphatemia and osteoporosis, while secondary hyperparathyroidism is due to physiological secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia. Surgical approach is the major treatment modality for majority of these patients with hyperparathyroidism. Pre-operative localization of hyperfunctioning glands may lead to minimally invasive surgery. The most commonly used imaging modality for this purpose is 99mTc-sestaMIBI, and supplemented by ultrasonography of the neck. However, the sensitivity and specificity is significantly lower in patients with multiple parathyroid lesions.

Recently, some investigators reported cases of parathyroid adenoma discovered incidentally on choline PET images performed for prostate cancer. 11C or 18F choline is a PET probe used in imaging prostate cancer and hepatocellular carcinoma. As a phospholipid analog, choline is integrated into newly synthesized membranes of proliferating cells by up-regulation of choline kinase. In addition, a previous study showed that the activity of phospholipid/Ca2+-dependent protein kinase was also higher in hyper-functioning parathyroid tissue than in atrophic parathyroid gland. Both mechanisms may be responsible for the uptake of choline tracers in hyperfunctioning parathyroid tissue. Up to now, there are only 3 original reports with limited patients using choline PET in the evaluation of hyperparathyroidism.

This prospective study aims to

1. compare the detection rates among sonography, MIBI scan and 18F-FCH PET for localization of the parathyroid lesions including adenoma, hyperplasia or carcinoma;

2. evaluate the usefulness of 18F-FCH PET as a second-line tracer in MIBI scan negative patients. ;

Study Design

Related Conditions & MeSH terms

Parathyroid Diseases

Clinical Trial Details

NCT number	NCT03555487
Study type	Interventional
Source	National Taiwan University Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	May 5, 2015
Completion date	October 1, 2018

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04589884` - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Completed	`NCT00569920` - Nausea and Pain Prophylaxis During Thyroid Surgery	N/A
Terminated	`NCT00639405` - Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas	N/A
Completed	`NCT04704349` - Latest Imaging SPECT System Evaluation Phase 1	N/A
Completed	`NCT03747029` - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed	`NCT03640247` - Pain Medications Following Thyroidectomy and Parathyroidectomy	Phase 1
Completed	`NCT04344886` - Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery	N/A
Completed	`NCT03469310` - Minimizing Narcotic Analgesics After Endocrine Surgery	Phase 4
Not yet recruiting	`NCT05243979` - The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut
Active, not recruiting	`NCT05778071` - Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism	Phase 3
Completed	`NCT02901873` - EIS in Thyroid and Parathyroid Surgery	N/A
Recruiting	`NCT04569513` - The Analysis of Thyroidectomy and Parathyroidectomy
Recruiting	`NCT05387070` - PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism	Phase 3
Not yet recruiting	`NCT05432050` - Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Recruiting	`NCT06274970` - PaThERAS: ERAS Protocols in Thyroid & Parathyroid Surgery	N/A
Enrolling by invitation	`NCT05294393` - Ropivacaine Plus Magnesium Sulphate Infiltration	Phase 4
Terminated	`NCT04745793` - Precise Recognition With Enhanced Vision of Endocrine Neck Targets
Recruiting	`NCT05152927` - Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy	N/A
Active, not recruiting	`NCT04701203` - A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism	Phase 3
Recruiting	`NCT05022667` - Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan. — parathyroid

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms